Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A Phase 1b/2a Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Aged 18 to 65 years at the time of consent.

• Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria.

• Active, seropositive disease, with SLEDAI 2K \>=6 at screening

• Inadequate response to at least one therapeutic intervention

Locations
Other Locations
China
Baoji Central Hospital
RECRUITING
Baoji
Peking University People's Hospital
RECRUITING
Beijing
The First Affiliated Hospital of Bengbu Medical College
NOT_YET_RECRUITING
Bengbu
Xiangya Second Hospital of Central South University
NOT_YET_RECRUITING
Changsha
The First Affiliated Hospital of the University of Science
NOT_YET_RECRUITING
Hefei
Mianyang Central Hospital
ACTIVE_NOT_RECRUITING
Mianyang
The First Affiliated Hospital of Nanchang
NOT_YET_RECRUITING
Nanchang
The Second Affiliated Hospital of Soochow University
NOT_YET_RECRUITING
Suzhou
Shanxi Bethune Hospital
RECRUITING
Taiyuan
Zaozhuang Municipal Hospital
NOT_YET_RECRUITING
Zaozhuang
Contact Information
Primary
Climb Bio Study Director
clinicaltrials@climbbio.com
+1 8668572596
Time Frame
Start Date: 2026-06-30
Estimated Completion Date: 2027-09
Participants
Target number of participants: 30
Treatments
Experimental: Cohort 1: Dose Level A
Single IV dose at Day 1 and Day 15
Experimental: Cohort 2: Dose Level B
Single IV dose at Day 1 and Day 15
Experimental: Cohort 3: Dose Level C
Single IV dose at Day 1 and Day 15
Experimental: Dose Expansion Cohort
Single IV dose at Day 1 and Day 15
Related Therapeutic Areas
Sponsors
Leads: Climb Bio, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials